Cargando…

Characteristics of drugs safety signals that predict safety related product information update

PURPOSE: Investigation of drug safety signals is one of the major tasks in pharmacovigilance. Among many potential signals identified, only a few reflect adverse drug reactions requiring regulatory actions, such as product information (PI) update. Limited information is available regarding the signa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Insani, Widya N., Pacurariu, Alexandra C., Mantel‐Teeuwisse, Aukje K., Gross‐Martirosyan, Liana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055643/ https://www.ncbi.nlm.nih.gov/pubmed/29797381 http://dx.doi.org/10.1002/pds.4446

Ejemplares similares

The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals
por: Ebbers, Hans C., et al.
Publicado: (2012)

Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study
por: Ogar, Comfort K., et al.
Publicado: (2023)

Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study
por: Sagwa, Evans L, et al.
Publicado: (2014)

Impact of regulatory requirements on medicine registration in African countries – perceptions and experiences of pharmaceutical companies in South Africa
por: Narsai, Kirti, et al.
Publicado: (2012)

Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification
por: Osokogu, Osemeke U., et al.
Publicado: (2016)

When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs
por: Callenbach, Marcelien H. E., et al.
Publicado: (2022)

The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study
por: Jacobs, Tom G., et al.
Publicado: (2018)

Regulatory scientific advice in drug development: does company size make a difference?
por: Putzeist, Michelle, et al.
Publicado: (2010)

The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia
por: Sagwa, Evans, et al.
Publicado: (2012)

Availability, prices and affordability of UN Commission’s lifesaving medicines for reproductive and maternal health in Uganda
por: Kibira, Denis, et al.
Publicado: (2017)

Effectiveness and Safety Profile of Alternative Tobacco and Nicotine Products for Smoking Reduction and Cessation: A Systematic Review
por: Zakiyah, Neily, et al.
Publicado: (2021)

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study
por: Roldan Munoz, Sonia, et al.
Publicado: (2023)

Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists
por: Bazargani, Yaser T., et al.
Publicado: (2014)

The double opioid crisis: A call for balance
por: Vranken, Marjolein J.M., et al.
Publicado: (2019)

Systematic reviews of ten pharmaceutical pricing policies – a research protocol
por: Tordrup, David, et al.
Publicado: (2020)

Disease awareness campaigns in printed and online media in Latvia: cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards
por: Leonardo Alves, Teresa, et al.
Publicado: (2018)

Drug development for exceptionally rare metabolic diseases: challenging but not impossible
por: Putzeist, Michelle, et al.
Publicado: (2013)

Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2015)

Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study
por: Ankrah, Daniel N. A., et al.
Publicado: (2017)

Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
por: Joosse, Iris R, et al.
Publicado: (2023)

Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study
por: Postma, Doerine J., et al.
Publicado: (2018)

Essential Medicines Are More Available than Other Medicines around the Globe
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Real World Data in Health Technology Assessment of Complex Health Technologies
por: Hogervorst, Milou A., et al.
Publicado: (2022)

Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study
por: Dankers, Marloes, et al.
Publicado: (2022)

Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019
por: Kusynová, Zuzana, et al.
Publicado: (2022)

Marketing of medicines in primary care: An analysis of direct marketing mailings and advertisements
por: Dankers, Marloes, et al.
Publicado: (2023)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients
por: Tetteh, Raymond A., et al.
Publicado: (2016)

National medicines policies – a review of the evolution and development processes
por: Hoebert, Joëlle M, et al.
Publicado: (2013)

Adverse events and patients’ perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia
por: Sagwa, Evans L, et al.
Publicado: (2016)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Impact of Over-the-Counter Restrictions on Antibiotic Consumption in Brazil and Mexico
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2013)

Compliance of Disease Awareness Campaigns in Printed Dutch Media with National and International Regulatory Guidelines
por: Leonardo Alves, Teresa, et al.
Publicado: (2014)

Essential medicines for breast cancer in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2015)

Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort
por: Sagwa, Evans L., et al.
Publicado: (2015)

Facilitators and barriers to antiretroviral therapy adherence among adolescents in Ghana
por: Ankrah, Daniel NA, et al.
Publicado: (2016)

Missing data on accessibility of children’s medicines
por: Joosse, Iris R, et al.
Publicado: (2022)

Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries
por: Leopold, Christine, et al.
Publicado: (2012)

Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses
por: Leopold, Christine, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ke4jvc6pv3i5uc48e53krb3q29